Statin Eligibility Prior to Myocardial InfarCtion (StatinEPIC)
Statin Eligibility Prior to Myocardial InfarCtion in Jordanians
The study (Statin Eligibility Prior to myocardial infarction (MI) in Jordanians, StatinEPIC) is
- Cross sectional
- Non interventional
- One encounter per patient. No follow up. It addresses a major issue of primary prevention in Jordanians especially the young population, namely the issue of lipid lowering agents before sustaining an acute MI. A recent study in USA showed that 50% of patients who sustained MI were not eligible to statins had they been evaluated before the heart attack. It is largely unknown if a larger percentage of Middle Eastern patients who sustain a heart attack would be eligible to receive lipid lowering agents.
- The PI will overlook the whole process. Dr Ahmad Tamari, the assistant to the PI will asses this whole process of data collection, management and manuscript drafting.
研究概览
详细说明
Statins, when use as primary cardiovascular prevention strategy, have been shown to lower future acute cardiovascular events, especially myocardial infarction. However the use of statins in this context (i.e., primary prevention) is governed by guidelines that limit the use of statins to four high risk populations: (1) hose with known cardiovascular disease, (2) those with low-density lipoprotein cholesterol (LDL-C) levels 190 mg/dl or above, (3) diabetics with LDL-C levels 70-189 mg/dl, and (4) those with an estimated 10-year atherosclerotic cardiovascular disease risk score of 7.5% or more.
Unfortunately, some individuals are still at risk of sustaining MI despite the fact that they do not fit into one of these four high risk groups eligible for statins.
StainEPIC will enroll consecutive patients admitted with MI who are not on statins to examine their eligibility for these medications based on the AHA/ACC guidelines.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Amman、约旦、11184
- Istishari Hospital
-
Amman、约旦、11942
- The university of Jordan
-
Amman、约旦
- Jordan Hospital
-
Amman、约旦
- Khalidi Hospital & Medical Center
-
Irbid、约旦
- King Abdullah University Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Adults admitted with MI, age 30 to 75
- known lipid profile
Exclusion Criteria:
- on statin before enrollment
学习计划
研究是如何设计的？
设计细节
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Eligible patients for statin therapy
大体时间：Within 24 hour of enrollment
|
The primary outcome is to calculate the percentage of enrolled patients who do meet the AHA/ACC Guidelines for receiving statins as a primary prevention measure.
|
Within 24 hour of enrollment
|
合作者和调查者
调查人员
- 研究主任：Yasmine Obeidat, MS、Hashemmeyyeh University School of Medicine, Zarka, Jordan
- 首席研究员：Ayman J Hammoudeh, MD, FACC、Istishari Hospital, Department of Cardiology, Amman, Jordan
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.
No intervention的临床试验
-
University of Illinois at ChicagoShirley Ryan AbilityLab; Oakland University; Access Living主动，不招人
-
University of Wisconsin, MadisonNational Cancer Institute (NCI); Northwestern University主动，不招人
-
Otsuka Pharmaceutical Factory, Inc.Celerion完全的